Prevalence and factors associated with long-term remission in cutaneous lupus: A longitudinal cohort study of 141 cases.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 35390427.
- Also identified by DOI 10.1016/j.jaad.2022.03.056.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Little is known about the prevalence and factors associated with long-term remission in cutaneous lupus erythematosus (CLE). To assess the prevalence, the factors associated with remission, and the long-term remission with and without treatment during CLE. Longitudinal cohort study including biopsy-proven patients with CLE seen between November 1, 2019 and April 30, 2021, with at least 6 months of follow-up after diagnosis. Demographic data, CLE subtypes, remission status, and treatments were recorded. Remission was defined by a Cutaneous Lupus Erythematosus Disease Area and Severity Index activity score of 0. Long-term remission was defined by remission >3 years. Among 141 patients included (81% of women), 93 (66%) were in remission at last follow-up with a median duration since diagnosis of 11.4 years (interquartile range, 4.2-24.7). Long-term remission was observed in 22 (19%) of 114 patients with at least 3 years of follow-up, including 5 (4.4%) with no systemic treatment. Active smoking (odds ratio, 0.22 [95%CI: 0.05-0.97]; P = .04) and discoid CLE lesions (odds ratio, 0.14 [95%CI, 0.04-0.48]; P = .004) were associated with a lower risk of long-term remission. Partial retrospective data collection and tertiary center population. Long-term remission is rare in CLE and negatively associated with active smoking and discoid CLE.
Medical subject headings
- Lupus Erythematosus, Cutaneous
- Lupus Erythematosus, Systemic